Direction at a glance
A scientifically successful intervention has limited public-health value if it cannot reach the populations and regions most affected by HIV. Equity research must begin during product design, not after approval.
What the evidence establishes
- Global treatment and prevention gaps remain despite highly effective biomedical tools.
- Complex delivery, intellectual property, workforce, monitoring and price can all limit population impact.
- Representation in trials affects the evidence available for adolescents, women, pregnant people, children and diverse regions.
Next decisive research questions
Limits and responsible interpretation
What this direction does not yet prove
Implementation evidence is context specific. Average effectiveness can hide unequal access and outcomes across populations.
Development pathway
| Decision | Required evidence |
|---|---|
| Biological activity | Target engagement and an outcome that cannot be explained by assay noise or selection. |
| Clinical value | Meaningful benefit, adequate follow-up, safety, comparison with current standard care and transparent uncertainty. |
| Generalizability | Diverse populations, subtypes, geographies, ages and clinically relevant comorbidities. |
| Scalability | Manufacturing, delivery, monitoring, price, workforce and community acceptability. |
Principal sources and evidence gateways
Links checked 18 August 202601
Global HIV & AIDS statistics — 2025 reporting yearUNAIDS · Dataset · Access checked 18 Aug 2026
↗02NIH Strategic Plan for HIV and HIV-Related Research, updated 2025NIH Office of AIDS Research · Research strategy · Access checked 18 Aug 2026
↗03WHO guidelines on lenacapavir for HIV prevention and testing strategiesWorld Health Organization · Guideline · Access checked 18 Aug 2026
↗04WHO updated recommendations on HIV clinical managementWorld Health Organization · Guideline · Access checked 18 Aug 2026
↗